Evidence map›Paper›PMID 32962744›Full record

ReviewMolecular neurodegeneration2020

Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.

Xiaoqi Wang, Weijie Huang, Li Su, Yue Xing, Frank Jessen, Yu Sun, Ni Shu, Ying Han

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular neurodegeneration, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 6 pooled it
20.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 6 syntheses or guidelines pooled it, 254 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Mandarin speech-based early detection of SCD: a feature-fusion residual network method.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Xiaoqi WangDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.
Weijie HuangState Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, 100875, China.
Li SuDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Yue XingRadiological Sciences, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.
Frank JessenDepartment of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, 50937, Cologne, Germany.
Yu SunDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China. wuyou91@126.com.
Ni ShuState Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, 100875, China. nshu@bnu.edu.cn.
Ying HanDepartment of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China. hanying@xwh.ccmu.edu.cn.ORCID 0000-0003-0377-7424
Capital Medical University · CNBeijing Normal University · CNMcGovern Institute for Brain Research · USSouthwest University · CNUniversity of Cologne · DEUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms of AD and identifying SCD-related biomarkers, which are critical for the early detection of AD. With the advent of advanced neuroimaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), accumulating evidence has revealed structural and functional brain alterations related to the symptoms of SCD. In this review, we summarize the main imaging features and key findings regarding SCD related to AD, from local and regional data to connectivity-based imaging measures, with the aim of delineating a multimodal imaging signature of SCD due to AD. Additionally, the interaction of SCD with other risk factors for dementia due to AD, such as age and the Apolipoprotein E (ApoE) ɛ4 status, has also been described. Finally, the possible explanations for the inconsistent and heterogeneous neuroimaging findings observed in individuals with SCD are discussed, along with future directions. Overall, the literature reveals a preferential vulnerability of AD signature regions in SCD in the context of AD, supporting the notion that individuals with SCD share a similar pattern of brain alterations with patients with mild cognitive impairment (MCI) and dementia due to AD. We conclude that these neuroimaging techniques, particularly multimodal neuroimaging techniques, have great potential for identifying the underlying pathological alterations associated with SCD. More longitudinal studies with larger sample sizes combined with more advanced imaging modeling approaches such as artificial intelligence are still warranted to establish their clinical utility.

Indexed as

Early DiagnosisAlzheimer DiseaseCognitive DysfunctionFemaleHumansMaleNeuroimagingAlzheimer’s diseasemultimodal MRIneuroimagingPETsubjective cognitive decline

Identifiers

PMID32962744
PMCPMC7507636
OpenAlexW3088567733

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.